Navigation Links
Sequella receives US and EU orphan drug status for SQ109 for the treatment of TB
Date:10/22/2007

ROCKVILLE, MD -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat diseases of epidemic potential, announced today that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) independently reviewed Sequella lead drug compound, SQ109, and both agencies granted SQ109 orphan drug status for the treatment of tuberculosis. SQ109 shows excellent in vitro and in vivo activity against drug-susceptible and drug-resistant TB bacteria, including XDR-TB. Further, SQ109 synergizes with other TB drugs in experimental animal models of TB, and could result in new TB drug combinations that have much greater activity than the current standard of care.

We are pleased that the FDA and the EMEA awarded Sequella orphan drug and orphan medicinal product status for the use of SQ109 (N-adamantany1-N-Geranyl-ehtylendiamine) for the treatment of tuberculosis (TB), a chronically debilitating and life-threatening infectious pulmonary and extrapulmonary disease, said Dr. Carol Nacy. With the resurgence of TB in a new drug-resistant form it is clear there is a need to readdress the treatment of this infectious and deadly disease. To accelerate our clinical programs, we will continue to work closely with the FDAs Office of Orphan Products Development and the EMEAs Committee for Orphan Medicinal Products as we move through the clinical and regulatory process.

The Orphan Drug Act (Public Law 97-414, enacted in 1983 and amended) provides for economic incentives to encourage pharmaceutical companies to develop drugs for rare diseases defined as those affecting fewer than 200,000 people in the United States. Orphan drug designation entitles Sequella, Inc. to seven years of market exclusivity for SQ109 for the treatment of patients with tuberculosis. Additional incentives for orphan drug development include tax credits related to certain development expenses, an exemption from the FDA user fee, and
'/>"/>

Contact: Alicia Moran
alicia@brightlinemedia.com
410-991-7027
Sequella
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. DuPonts first biologically derived polymer receives global recognition
2. OneWorld Health drug receives Orphan designation from U.S. and European regulatory agencies
3. Research on antibiotics receives historical recognition
4. Anthrax test, developed by army and CDC, receives FDA approval
5. Research team receives $7.5 million to study cassava
6. Virulizin granted orphan drug status in Europe
7. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
8. Sudden change in social status triggers genetic response in male fish, study finds
9. Gene expression test reveals ER and HER-2 status of breast tumors
10. MU researchers to study the status of black bears in Missouri
11. Protein discovery could unlock the secret to better TB treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... group decision increases with the abundance of brains involved ... variety of factors as often happens in life ... groups actually tend to make more accurate decisions while ... pieces of information. , The findings present a significant ... the "wisdom of crowds," wherein individual observations even ...
(Date:4/23/2014)... newly coined term for novels and films which focus on ... Copenhagen shows how these fictions serve as a mental laboratory ... change and imagine other living conditions. , "Global warming ... atmosphere; it is also a cultural phenomenon in which meaning ... films we see. And there are so many of them ...
(Date:4/23/2014)... HOUSTON, April 23, 2014 A biomedical engineer at ... highly innovative technology to make blood transfusions safer. His ... the National Institutes of Health (NIH). , Blood ... one of modern medicine,s absolute necessities. Without them, for ... mean transfusions are perfect, however. There,s strong evidence that ...
Breaking Biology News(10 mins):Too many chefs: Smaller groups exhibit more accurate decision-making 2Too many chefs: Smaller groups exhibit more accurate decision-making 3Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3
... More than 450 world experts from 60 countries will ... DNA "barcoding" - a rapidly growing international initiative to develop ... Earth. The Fourth International Barcode of Life Conference ... from Wednesday 30 November to Saturday 3 December. ...
... years ago, two teams of explorers raced to be the first ... South Pole on December 14, 1911. , Thirty-three days later ... Falcon Scott arrived at the Pole in second place. At ... by Douglas Mawson was searching for the South Magnetic Pole. ...
... surface of an implant such as a new hip or ... and researchers at the University of Gothenburg, Sweden, can now ... are presented in the International Journal of Nanomedicine . ... of the most common reasons for an implant being rejected," ...
Cached Biology News:Seaweed hotspots, illegal logging, and discovering new species under the desert 2Seaweed hotspots, illegal logging, and discovering new species under the desert 3Seaweed hotspots, illegal logging, and discovering new species under the desert 4Climate change stunting growth of century-old Antarctic moss shoots 2Cobblestones fool innate immunity 2
(Date:1/15/2014)... laureate Herbert Kroemer famously observed, referring to the ... where layers of different materials meet. In today,s ... of metal oxides are becoming increasingly prominent, with ... superconductors, ferroelectrics and multiferroics. Realizing the vast potential ...
(Date:1/15/2014)... 2014 The Pittcon Organizing Committee is pleased ... Safety Tech , an e-Journal and producer of ... the second year for the co-location of Food Labs Conference ... provides that the registration fee to attend the two-day Food ...
(Date:1/15/2014)... Look inside the new Preferred Solutions® catalog ... from fluid handling to instruments to supplies. Many items ... order. , Preferred Solutions features a full selection ... model for precise flow control and dispensing to I/P® ...
(Date:1/15/2014)... OXFORD, England and SAN JOSE, California ... an international biotechnology company developing antibody-drug conjugates for cancer, today ... its Board of Directors. Dr Reynolds has over 20 years, ... Chief Medical Officer at Seattle Genetics. "I am ...
Breaking Biology Technology:A deeper look at interfaces 2Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3
... May 9, 2011 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, ... or "AOB"), a pharmaceutical company dedicated to improving ... a broad range of prescription and over–the-counter ("OTC") ... quarter ended March 31, 2011. ...
... Fla., May 9, 2011 Dyadic International, Inc. ... focused on the discovery, development, manufacture and sale ... industrial enzyme and biopharmaceutical industries, today announced that ... and development center in The Netherlands, will be ...
... 9, 2011 Ardea Biosciences, Inc. (Nasdaq: ... of small-molecule therapeutics for the treatment of serious diseases, ... first quarter ended March 31, 2011. "Results from our ... with allopurinol demonstrate lesinurad,s potential to bring relief to ...
Cached Biology Technology:American Oriental Bioengineering Reports First Quarter 2011 Financial Results 2American Oriental Bioengineering Reports First Quarter 2011 Financial Results 3American Oriental Bioengineering Reports First Quarter 2011 Financial Results 4American Oriental Bioengineering Reports First Quarter 2011 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 2Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 3Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 4Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results 6
APG5 autophagy 5-like (S. cerevisiae)...
...
Griess Reagent component for determination of nitrite in aqueous solutions....
... terminators, template DNA, primers, salts or other ... have proved critical for both standard and ... work with dye terminator cycle sequencing chemistries ... unique uniformity of the magnetic paeticles guarantees ...
Biology Products: